)
Jubilant Life Sciences has soared 6% to Rs 169 on BSE after the pharmaceutical company said it has received final approval from the US Food and Drug Administration (US FDA) for generic Montelukast Sodium chewable tablets used in the treatment of asthma and to relieve symptoms of seasonal allergies.
The total market size for Montelukast tablets as per IMS is $83 Million per annum, Jubilant Life Sciences said in a statement.
As on December 31, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally. This includes 72 abbreviated new drug application (ANDAs) filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. So far, we have received 10 ANDA approvals during FY 2015, it added.
The stock opened at Rs 168 and touched a high of Rs 175 on BSE. A combined about one million shares changed hands on the counter till 1002 hours on BSE and NSE.
The total market size for Montelukast tablets as per IMS is $83 Million per annum, Jubilant Life Sciences said in a statement.
As on December 31, 2014, Jubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally. This includes 72 abbreviated new drug application (ANDAs) filed in the US, of which 35 have been approved and 46 Dossier filings in Europe. So far, we have received 10 ANDA approvals during FY 2015, it added.
The stock opened at Rs 168 and touched a high of Rs 175 on BSE. A combined about one million shares changed hands on the counter till 1002 hours on BSE and NSE.
